Who can participate in the study?
- Adults aged 18 and over who have been diagnosed with PPF (not idiopathic pulmonary fibrosis)
- Candidates who meet the spirometry test requirements
- Candidates who meet other study requirements that the study doctors have established
Why participate in the study?
There is no cure for PPF. Current treatments in tablet form can slow the disease in some people. However, high doses are required for swallowed medication to reach the lungs, which may cause side effects.
Researchers want to know if an inhaled form of pirfenidone (AP01) can improve lung function and have fewer side effects.
New treatments are developed through clinical research studies. By volunteering to participate in a study, you can help researchers learn more about FPP.
What to expect
- A period of 12 months (or more, for participants who choose to continue in an extension study)
- The study drug or a placebo will be inhaled by nebulizer twice a day
- Medical exams and tests at most appointments
- Many study centers around the world
- Study exams, tests and treatments are provided for free to the participants.
- Frequent meetings with study doctors
Learn more:
Study promoter:
Avalyn Pharma is a biopharmaceutical company focused on developing drugs for rare lung diseases.
Talk to your doctor to find out if the MIST study is an option for you.
AP01 is an investigational drug-device combination and is not approved by any health authority.
For further information, please contact:
Daphnée Blanchet-Paquin, Nurse Research Coordinator
Telephone: 873 240-5128
www.cic-mauricie.ca
Health
